As of Nov 27
| +0.10 / +1.12%|
The 5 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 13.00, with a high estimate of 16.00 and a low estimate of 9.50. The median estimate represents a +44.44% increase from the last price of 9.00.
The current consensus among 5 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.